Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Accumulated Expenses (2020 - 2025)

Tango Therapeutics has reported Accumulated Expenses over the past 6 years, most recently at $17.8 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $17.8 million for Q4 2025, up 7.65% from a year ago — trailing twelve months through Dec 2025 was $17.8 million (up 7.65% YoY), and the annual figure for FY2025 was $17.8 million, up 7.65%.
  • Accumulated Expenses for Q4 2025 was $17.8 million at Tango Therapeutics, up from $13.1 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for TNGX hit a ceiling of $17.8 million in Q4 2025 and a floor of $202089.0 in Q1 2021.
  • Median Accumulated Expenses over the past 5 years was $11.1 million (2023), compared with a mean of $10.6 million.
  • Biggest five-year swings in Accumulated Expenses: surged 13312.37% in 2021 and later fell 27.2% in 2023.
  • Tango Therapeutics' Accumulated Expenses stood at $9.9 million in 2021, then soared by 76.95% to $17.5 million in 2022, then decreased by 11.97% to $15.4 million in 2023, then increased by 7.12% to $16.5 million in 2024, then grew by 7.65% to $17.8 million in 2025.
  • The last three reported values for Accumulated Expenses were $17.8 million (Q4 2025), $13.1 million (Q3 2025), and $11.5 million (Q2 2025) per Business Quant data.